Full Press Release Details
Solutions Adds Chief Technology Officer to Leadership Team
Experts from Partner Icahn Institute at Mount Sinai Form Science Team
ALAMEDA, Calif.--(BUSINESS WIRE)--October 1, 2014--BioTime, Inc. (NYSE
MKT:BTX) and its subsidiary LifeMap Solutions, Inc., a medical
technology company, today announced significant additions to the LifeMap
Solutions management team. LifeMap Solutions is partnering with the
Icahn Institute at Mount Sinai to create innovative mobile health
(mHealth) products and services backed by big data. Today the company
announced the appointment of Rafhael Cedeno as Chief Technology Officer
and Head of Product, as well as the addition of Joel Dudley, PhD, Rong
Chen, PhD, and Elissa Levin from the Icahn Institute as members of the
LifeMap Solutions science team.
A veteran in big data and consumer technology applications, Rafhael
Cedeno comes to LifeMap Solutions with significant experience at
Internet and software companies, including his previous role as Vice
President of Game Development for Viacom, where he oversaw the
development of top-charting iOS and Android apps on the Apple App Store
and Google Play, respectively, and provided technical and product
direction for other projects at Viacom. Earlier in his career, Mr.
Cedeno worked at such influential Internet companies as Netscape and
Kontiki. As Chief Technology Officer and Head of Product, Mr. Cedeno
will be responsible for overseeing all aspects of product development,
including the integration of Mount Sinai's expertise and data into
LifeMap Solutions' products.
"Adding Rafhael Cedeno to our team is a major win for us," said LifeMap
Solutions CEO Corey Bridges. "He brings to LifeMap Solutions his
experience architecting and managing the development of complex
technology platforms, coupled with the bold innovation he applies to
product design. His history of success in the mobile space meshes
perfectly with our needs."
"This is an exciting time to work in health technology. We are living in
an era characterized by an unprecedented ability to analyze enormous
quantities of data from sources that weren't easily accessible
previously," said Mr. Cedeno. "As we work alongside our partners at
Mount Sinai, we are uniquely poised to make an impact in the industry."
In addition, LifeMap Solutions today announced the names of the new
members of the company's science team from their partner, the Icahn
Institute at Mount Sinai:
Joel Dudley, PhD, Director of Biomedical Informatics
Elissa Levin, MS, CGC, Head of Genomics and Integrative Health
Rong Chen, PhD, Director of Clinical Genome Informatics
Eric Schadt, PhD, founding director of the Icahn Institute for Genomics
and Multiscale Biology at Mount Sinai, was previously announced as the
leading science advisor to LifeMap Solutions. The science team will
coordinate with Mr. Cedeno to share knowledge and expertise to build
mHealth products and services.
About LifeMap Solutions, Inc.
LifeMap Solutions is developing innovative mobile health technology in
partnership with the Icahn Institute for Genomics and Multiscale Biology
at the Icahn School of Medicine at Mount Sinai. LifeMap Solutions is a
member of the BioTime family of companies (NYSE MKT: BTX) and is
developing relatively near-term commercial applications of technologies
generated at the Icahn School of Medicine. LifeMap Solutions is
headquartered in Alameda, California. For more information, please visit www.lifemap-solutions.com.
BioTime is a biotechnology company engaged in research and product
development in the field of regenerative medicine. Regenerative medicine
refers to therapies based on stem cell technology that are designed to
rebuild cell and tissue function lost due to degenerative disease or
injury. BioTime's focus is on pluripotent stem cell technology based on
human embryonic stem ("hES") cells and induced pluripotent stem ("iPS")
cells. hES and iPS cells provide a means of manufacturing every cell
type in the human body and therefore show considerable promise for the
development of a number of new therapeutic products. BioTime's
therapeutic and research products include a wide array of proprietary PureStem
progenitors, HyStem hydrogels, culture media,
and differentiation kits. BioTime is developing Renevia (a HyStem
product) as a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications, and is planning
to initiate a pivotal clinical trial around Renevia , in 2014. In
addition, BioTime has developed Hextend , a blood
plasma volume expander for use in surgery, emergency trauma treatment
and other applications. Hextend is manufactured
and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ
HealthCare Corporation, under exclusive licensing agreements.
BioTime is also developing stem cell and other products for research,
therapeutic, and diagnostic use through its subsidiaries:
Asterias Biotherapeutics, Inc. is developing pluripotent stem-cell
based therapies in neurology and oncology, including AST-OPC1
oligodendrocyte progenitor cells in spinal cord injury, multiple
sclerosis and stroke, and AST-VAC2, an allogeneic dendritic cell-based
cancer vaccine. Asterias trades publicly under the symbol ASTY.
BioTime Asia, Ltd., a Hong Kong company, may offer and sell products
for research use for BioTime's ESI BIO Division.
Cell Cure Neurosciences Ltd. is an Israel-based biotechnology company
focused on developing stem cell-based therapies for retinal and
neurological disorders, including the development of retinal pigment
epithelial cells for the treatment of macular degeneration, and
treatments for multiple sclerosis.
ESI BIO is the research and product marketing division of BioTime,
providing stem cell researchers with products and technologies to
enable them to translate their work into the clinic, including PureStem
progenitors and HyStem hydrogels.
LifeMap Sciences, Inc. markets, sells, and distributes GeneCards ,
the leading human gene database, as part of an integrated database
suite that also includes the LifeMap Discovery
database of embryonic development, stem cell research, and
regenerative medicine, and MalaCards, the human disease
LifeMap Solutions, Inc. is a subsidiary of LifeMap Sciences focused on
developing mobile health (mHealth) products.
OncoCyte Corporation is developing products and technologies to